Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of Tuesday, October 6, 2026.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
Conexeu Sciences Inc.
Market Cap
$83.49M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.96M
Return on Invested Capital (ROIC)
-109.43%
TTM Avg
-208.02%
3Y Avg
-178.83%
5Y Avg
-203.50%
Market Cap
$84.00M
Return on Invested Capital (ROIC)
-90.27%
TTM Avg
-103.33%
3Y Avg
-85.38%
5Y Avg
-72.83%
Market Cap
$84.70M
Return on Invested Capital (ROIC)
-100.35%
TTM Avg
-639.99%
3Y Avg
-358.78%
5Y Avg
-266.51%
Market Cap
$84.75M
Return on Invested Capital (ROIC)
-88.28%
TTM Avg
-61.59%
3Y Avg
-48.92%
5Y Avg
-67.61%
Market Cap
$81.22M
Return on Invested Capital (ROIC)
-88.72%
TTM Avg
-42.77%
3Y Avg
-39.33%
5Y Avg
-39.33%
Market Cap
$86.69M
Return on Invested Capital (ROIC)
12.79%
TTM Avg
17.38%
3Y Avg
-11.40%
5Y Avg
-8.36%
Market Cap
$79.46M
Return on Invested Capital (ROIC)
-836.58%
TTM Avg
-213.85%
3Y Avg
-158.30%
5Y Avg
-121.35%
Market Cap
$87.86M
Return on Invested Capital (ROIC)
-159.30%
TTM Avg
-82.85%
3Y Avg
-66.58%
5Y Avg
-50.22%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -109.43% | -208.02% | -178.83% | -203.50% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -90.27% | -103.33% | -85.38% | -72.83% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | -100.35% | -639.99% | -358.78% | -266.51% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -88.28% | -61.59% | -48.92% | -67.61% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -88.72% | -42.77% | -39.33% | -39.33% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 12.79% | 17.38% | -11.40% | -8.36% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -836.58% | -213.85% | -158.30% | -121.35% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -159.30% | -82.85% | -66.58% | -50.22% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 8.16% | 0.11% | -4.79% | -3.69% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
